National Institute for Health and Care Excellence (Nice)

The National Institute for Health and Care Excellence (NICE) is a UK-based organization that provides national guidance and advice to improve health and social care. NICE's role is to evaluate the clinical and cost-effectiveness of new and existing treatments and technologies, and to develop guidelines for healthcare professionals and the public. NICE is in the news recently due to several key decisions. Firstly, they authorized the use of Veoza (fezolinetant), a drug that prevents hot flushes, for use on the NHS in England, potentially benefiting over 500,000 women experiencing menopause. Secondly, the organization's role is implicitly highlighted in discussions around ADHD diagnosis and treatment pathways, particularly the challenges patients face navigating between private diagnoses and NHS care. Finally, NICE's role in evaluating new Alzheimer's therapies is relevant, especially with the emergence of drugs targeting toxic proteins in the brain, and calls for research to focus on specific genes linked to the condition. NICE's decisions significantly impact access to treatments and the direction of healthcare in England.